Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 8/20 | 1.00 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.73 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.73 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | ALPL | P05186 | 6/20 | 0.41 |
| ▸ | PGR | P06401 | 6/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1605339 | 0.89 | CYP11B2 (0.80) | CYP11B2CYP11B1CYP19A1MAOAPGR | |
| SCHEMBL7949460 | 0.88 | CYP11B2 (0.78) | CYP11B2CYP11B1CYP19A1MAOAALPL | |
| SCHEMBL1606929 | 0.87 | CYP11B2 (0.78) | CYP11B2CYP11B1CYP19A1MAOAALPL | |
| SCHEMBL1687013 | 0.87 | CYP11B2 (1.00) | CYP11B2CYP11B1CYP19A1MAOAPGR | |
| SCHEMBL1606130 | 0.85 | CYP11B2 (1.00) | CYP11B2CYP11B1CYP19A1MAOA | |
| SCHEMBL30385209 | 0.85 | CYP11B2 (1.00) | CYP11B2CYP11B1CYP19A1MAOA | |
| SCHEMBL1606966 | 0.83 | CYP11B2 (0.71) | CYP11B2CYP11B1CYP19A1MAOA | |
| SCHEMBL1607174 | 0.83 | CYP11B2 (0.71) | CYP11B2CYP11B1CYP19A1MAOA | |
| SCHEMBL7948350 | 0.82 | CYP11B2 (0.69) | CYP11B2CYP11B1CYP19A1MAOAALPL | |
| SCHEMBL19417552 | 0.82 | CYP11B2 (0.69) | CYP11B2CYP11B1CYP19A1MAOAALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307371-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | disclosed |
| US-9242963-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9242963-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150210672-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150210672-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20140288126-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-8791141-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-8791141-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-8030334-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| US-8030334-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| US-8030334-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| EP-2307371-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| WO-2009156462-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082129-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | CYP11B2 13/4885CYP11B1 14/4885CYP19A1 68/4885 |
| US-20100261698-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | CYP11B2 13/4885CYP11B1 14/4885CYP19A1 68/4885 |
| US-20150210672-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | CYP11B2 12/4885CYP11B1 15/4885CYP19A1 55/4885 |
| US-20140288126-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | CYP11B2 12/4885CYP11B1 15/4885CYP19A1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.